Lead sponsor
Supernus Pharmaceuticals, Inc.
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
0
Ongoing
200
Total enrollment
47
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
2
Trials by status
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)Alzheimer's diseasePh 2Completed174